International audienceBACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) is the most common potentially life threatening inherited kidney disease and is responsible for 5-10% of cases of end-stage kidney disease (ESKD). Cystic kidneys may enlarge up to 20 times the weight of a normal kidney due to the growth of renal cysts, and patients with ADPKD have an increased risk of morbidity, premature mortality, and other life-time complications including renal and hepatic cyst and urinary tract infection, intracranial aneurysm, diverticulosis, and kidney pain which impair quality of life. Despite some therapeutic advances and the growing number of clinical trials in ADPKD, the outcomes that are relevant to patients and clinicians, su...
AIM: Patients with autosomal dominant polycystic kidney disease (ADPKD) are at increased risk of pre...
Aim: Patients with autosomal dominant polycystic kidney disease (ADPKD) are at increased risk of pre...
International audienceAbstract Background Globally, over 1.2 million people die from chronic kidney ...
Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most common potentially life...
Autosomal dominant polycystic kidney disease (ADPKD) is the most common potentially life threatening...
Abstract Background Autosomal dominant polycystic kid...
Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most common potentially life...
The omission of outcomes that are of relevance to patients, clinicians, and regulators across trials...
International audienceThe omission of outcomes that are of relevance to patients, clinicians, and re...
The omission of outcomes that are of relevance to patients, clinicians, and regulators across trials...
The omission of outcomes that are of relevance to patients, clinicians, and regulators across trials...
Rationale & Objective: Outcomes reported in trials involving patients with autosomal dominant polycy...
RATIONALE & OBJECTIVE: Outcomes reported in trials involving patients with autosomal dominant polycy...
AIM: Patients with autosomal dominant polycystic kidney disease (ADPKD) are at increased risk of pre...
Aim: Patients with autosomal dominant polycystic kidney disease (ADPKD) are at increased risk of pre...
International audienceAbstract Background Globally, over 1.2 million people die from chronic kidney ...
Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most common potentially life...
Autosomal dominant polycystic kidney disease (ADPKD) is the most common potentially life threatening...
Abstract Background Autosomal dominant polycystic kid...
Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most common potentially life...
The omission of outcomes that are of relevance to patients, clinicians, and regulators across trials...
International audienceThe omission of outcomes that are of relevance to patients, clinicians, and re...
The omission of outcomes that are of relevance to patients, clinicians, and regulators across trials...
The omission of outcomes that are of relevance to patients, clinicians, and regulators across trials...
Rationale & Objective: Outcomes reported in trials involving patients with autosomal dominant polycy...
RATIONALE & OBJECTIVE: Outcomes reported in trials involving patients with autosomal dominant polycy...
AIM: Patients with autosomal dominant polycystic kidney disease (ADPKD) are at increased risk of pre...
Aim: Patients with autosomal dominant polycystic kidney disease (ADPKD) are at increased risk of pre...
International audienceAbstract Background Globally, over 1.2 million people die from chronic kidney ...